Bli medlem
Bli medlem

Du är här

2017-11-08

AstraZeneca: AstraZeneca shares scientific updates from its extensive cardiovascular, renal and metabolic diseases (CVMD) p...

AstraZeneca and MedImmune, its global biologics research and
development arm, will be underlining its scientific focus on
cardiovascular, renal and metabolic diseases (CVMD) with 28
presentations, including two late-breaking trials, at the American
Heart Association (AHA) Scientific Sessions, November 11-15, 2017 in
Anaheim, California.

Ludovic Helfgott, Vice President, Cardiovascular and Metabolic
Diseases, said: "With the breadth of our scientific updates at AHA
2017, we are at the forefront of the clinical debate, exploring the
often unseen but vital connections between cardiovascular, renal and
metabolic diseases. This approach embodies our commitment to
improving outcomes for patients while reducing long-term morbidity
and mortality."

Key among the data being presented are two late-breaking presentations
selected by the AHA: the China-based DACAB study (Efficacy of
Different Antiplatelet Therapy Strategy after Coronary Artery Bypass
Grafting); and the EXSCEL (EXenatide Study of Cardiovascular Event
Lowering) trial, plus data for potential new CVMD medicines.

· The DACAB study compares the use of Brilinta (ticagrelor) plus
aspirin versus aspirin alone, and Brilinta alone following elective
coronary artery bypass graft surgery (CABG), to assess patency of the
grafts. (Session LBS.01)

· A new analysis of the EXSCEL clinical trial, the largest and most
inclusive CV outcomes trial of any glucagon-like peptide-1 receptor
agonist (GLP-1 RA), with more than 14,500 patients at 687 trial sites
across 35 countries, aims to further demonstrate the effect of
Bydureon (exenatide) once-weekly on CV morbidity and mortality in
patients with type-2 diabetes. This new analysis adds to results
presented at the recent annual meeting of the European Association
for the Study of Diabetes (EASD), and published simultaneously in the
New England Journal of Medicine
(http://www.nejm.org/doi/full/10.1056/NEJMoa1612917). (Session
LBS.04)

· Presentations at AHA also include early stage data for potential
new medicines, as monotherapy and in combinations, in areas including
cardiac regeneration, chronic kidney disease, acute coronary
syndromes, and chronic heart failure. These include Phase IIa data of
MEDI6012, a recombinant human lecithin-cholesterol acyltransferase
(LCAT) being evaluated for the treatment of coronary artery disease
(Session LB.APS.06 - S2107) and CHF, as well as data from AZD5718 our
5-lipoxygenase activating protein (FLAP), a potential treatment for
ACS (Session IN.APS.02 - S4093).

ENDS

NOTES TO EDITORS

For the full listing of AstraZeneca/MedImmune Presentations at AHA
2017, please visit http://www.abstractsonline.com/pp8/#!/4412/

About AstraZeneca in Cardiovascular, Renal & Metabolic Diseases (CVMD)

Cardiovascular, renal and metabolic diseases together form one of
AstraZeneca's main therapy areas and platforms for future growth. By
following the science to understand more clearly the underlying links
between the heart, kidney and pancreas, AstraZeneca is investing in a
portfolio of medicines to protect organs and improve outcomes by
slowing disease progression, reducing risks and tackling
co-morbidities. Our ambition is to modify or halt the natural course
of CVMDs and even regenerate organs and restore function, by
continuing to deliver transformative science that improves treatment
practices and CVMD health for millions of patients worldwide.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular & Metabolic Diseases
and Respiratory. The Company also is selectively active in the areas
of autoimmunity, neuroscience and infection. AstraZeneca operates in
over 100 countries and its innovative medicines are used by millions
of patients worldwide.

For more information, please visit www.astrazeneca.com and follow us
on Twitter @AstraZeneca.

Media
Relations
Esra Erkal UK/Global +44 203 749 5638
-Paler
Karen UK/Global +44 203 749 5634
Birmingham
Rob UK/Global +44 203 749 5821
Skelding
Matt Kent UK/Global +44 203 749 5906
Gonzalo UK/Global +44 203 749 5916
Viña
Jacob Lund Sweden +46 8 553 260 20
Michele US +1 302 885 2677
Meixell

Investor
Relations
Thomas +44 203 749 5712
Kudsk
Larsen
Craig Finance, Fixed Income, M&A +44 7881 615 764
Marks
Henry Oncology +44 203 749 5797
Wheeler
Mitchell Oncology +1 240 477 3771
Chan
Christer Diabetes; Autoimmunity, Neuroscience & Infection +44 203 749 5711
Gruvris
Nick Stone Respiratory; Brilinta +44 203 749 5716
US toll +1 866 381 7277
free

-----------------------------------------------------------
http://news.cision.com/se/astrazeneca/r/astrazeneca-shares-scientific-up...

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.